Our strategy
Our strategy EVOLVE+ paves the way to further strengthen Siegfried’s position as a leading global integrated provider of development and manufacturing services. It builds on the cornerstones of the EVOLVE strategy which has enabled Siegfried to grow successfully and increase profitability in recent years.
The trends driving our sustainable business model
Pharmaceutical companies increasingly outsource manufacturing, focusing instead on their fundamental value drivers:
Increased focus on R&D and marketing and distribution
Pharmaceutical companies are shifting their focus from in-house process development and production, opting for a more asset light manufacturing set-up. Instead of investing into captive manufacturing capacities they focus on key value drivers such as R&D, marketing and distribution.
Need for flexible production
Changing growth trajectories and various requirements along the lifecycle of a drug can be met by a flexible outsourced capacity rather than a static captive manufacturing capacity of a pharma company, whilst at the same time benefiting from the increased economies of scale of a CDMO that can better utilize its capacity.
Increased importance of small and medium pharmaceutical players
A large proportion of the pharmaceutical development pipeline originates from small to mid-sized pharmaceutical companies, which are very reserved with respect to investing in in-house process development or manufacturing capacities, relying instead on outsourcing to a large extent.
Increased complexity of the pharmaceutical supply chain
New pharmaceutical entities and medicinal therapies are often facing more complex development and manufacturing challenges. Hence, these products benefit even more from an integrated offering of drug substances and drug products by reducing supply chain complexity as well as “time-to-market”.
Proactive lifecycle management
During the lifecycle of a drug, innovative pharmaceutical companies are faced with changing demand patterns, which require a corresponding adaptation of manufacturing capacities. Large scale, diversified CDMOs can adapt their manufacturing portfolio more flexibly to the needs of their customers.
Our business model
Our integrated approach ensures a comprehensive range of services from process development and optimization to registration, production, packaging and logistics, addressing the challenges of the outsourcing trend in the pharmaceutical industry.
Our EVOLVE+ strategy
The strategy EVOLVE + sharpens Siegfried’s focus on commercial, development, and operational excellence and the expansion of the technological offering to drive profitable growth.
The most important fields of action of EVOLVE + are:
- Expand Siegfried’s core business and grow new areas to further develop the scale and strengths of the global network
- Broaden the range of technologies and services, further enhancing Siegfried’s customer offering from early phase to commercial production
- Sharpen focus on commercial, development, and operational excellence to accelerate profitable growth
- Continue value accretive M&A as a catalyst to drive growth on all levels
For more information, read the media release.